Acurx Pharmaceuticals (ACXP)
1.15
+0.01 (0.88%)
Upcoming Events
Latest Headlines
Acurx antibiotic study published in ASM journal shows microbiome data
October 21, 2026 8:02 AM - StreetInsider
Acurx Announces Publication in ASM Confirming Data on its DNA pol IIIC Inhibitor Pipeline of Antibiotics Demonstrating a Potential Microbiome-Sparing Class Effect
October 21, 2026 8:01 AM - PR NewsWire
Form 8-K Acurx Pharmaceuticals, For: Oct 16
October 16, 2026 4:31 PM - SEC Filing
Acurx Pharmaceuticals Takes Its Antibiotics Story Global Through a 12-Month Series with New to The Street
October 5, 2026 1:26 PM - StreetInsider
Acurx enrolls first patient in PATHFINDER trial for C. difficile
September 29, 2026 8:02 AM - StreetInsider
Acurx Pharmaceuticals Announces First Patient Enrolled in PATHFINDER Clinical Trial of Ibezapolstat in Multiply-Recurrent C. difficile Infection
September 29, 2026 8:01 AM - PR NewsWire
New to The Street Broadcasts Tonight at 6:30 PM ET Across the United States, Latin America and MENA, Featuring BioVie, Acurx Pharmaceuticals, Lantern Pharma and SafeSpace Global
September 19, 2026 11:46 AM - StreetInsider
Form EFFECT Acurx Pharmaceuticals,
September 18, 2026 6:03 AM - SEC Filing
Form 424B3 Acurx Pharmaceuticals,
September 17, 2026 4:52 PM - SEC Filing
Acurx Announces Presentation of a Scientific Poster at the Premier International C. difficile Symposium (ICDS) Demonstrating Superior In Vitro Kill Kinetics of Ibezapolstat vs. Vancomycin and Fidaxomi
September 14, 2026 8:01 AM - PR NewsWire
Acurx gets FDA conditional brand name acceptance for CDI drug
August 17, 2026 8:02 AM - StreetInsider
Acurx Pharmaceuticals Receives FDA Conditional Acceptance and USPTO Trademark Allowance for the Company's Brand Name for Ibezapolstat
August 17, 2026 8:01 AM - PR NewsWire
Acurx Pharmaceuticals (ACXP) Tops Q2 EPS by 4c
August 14, 2026 7:02 AM - StreetInsider
Acurx Pharmaceuticals, Inc. Reports Second Quarter 2026 results and provides business update
August 14, 2026 7:01 AM - PR NewsWire
Form 10-Q Acurx Pharmaceuticals, For: Jun 30
August 13, 2026 4:09 PM - SEC Filing
Japan and Mexico grant Acurx Pharmaceuticals patents for antibiotic class
August 12, 2026 8:01 AM - StreetInsider
Japan and Mexico Patent Offices Both Grant Acurx Pharmaceuticals New Patents for DNA Polymerase IIIC Inhibitor Antibiotics
August 12, 2026 8:01 AM - PR NewsWire
Acurx partners with Leiden University to study MRSA antibiotic target
August 10, 2026 8:02 AM - StreetInsider
Acurx Announces Scientific Partnership with Leiden University Medical Center to Advance Development of Acurx's DNA Polymerase IIIC Inhibitor Antibiotics
August 10, 2026 8:01 AM - PR NewsWire
FDA offers Acurx path to NDA with single Phase 3 trial for CDI drug
August 3, 2026 8:00 AM - StreetInsider
FDA Provides Further Regulatory Guidance to Acurx Pharmaceuticals for the Ibezapolstat Clinical Development Program, Including the Potential for a Single-Phase 3-Trial Registration Plan and a Trial De
August 3, 2026 8:00 AM - PR NewsWire
Full Article List
